Satvir S. Tevethia All publications ( 47 ) Tagaram HR. Watson AM. Lemonnier FA. Staveley-O'Carroll K. Tevethia SS. Schell TD. An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants. 2008 Jun 20. Virology. 376(1):183-90. Yorty JL. Tevethia SS. Schell TD. Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. 2008 Jun. Cancer Immunol Immunother. 57(6):883-95. Otahal P. Knowles BB. Tevethia SS. Schell TD. Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors. 2007 Nov 15. J Immunol. 179(10):6686-95. Mylin LM. Schell TD. Epler M. Kusuma C. Assis D. Matsko C. Smith A. Allebach A. Tevethia SS. Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. 2007 Jul 20. Virology. 364(1):155-68. National Center for Research Resources National Heart, Lung, and Blood Institute National Cancer Institute Otahal P. Schell TD. Hutchinson SC. Knowles BB. Tevethia SS. Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. 2006 Sep 1. J Immunol. 177(5):3089-99. National Cancer Institute Sullivan CS. Grundhoff A. Tevethia S. Treisman R. Pipas JM. Ganem D. Expression and Function of MicroRNAs in Viruses Great and Small. 2006. Cold Spring Harb Symp Quant Biol. 71:351-356. Otahal P. Hutchinson SC. Mylin LM. Tevethia MJ. Tevethia SS. Schell TD. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. 2005 Jul 15. J Immunol. 175(2):700-12. National Cancer Institute Barton LF. Runnels HA. Schell TD. Cho Y. Gibbons R. Tevethia SS. Deepe GS. Monaco JJ. Immune defects in 28-kDa proteasome activator gamma-deficient mice. 2004 Mar 15. J Immunol. 172(6):3948-54. National Institute of Allergy and Infectious Diseases National Cancer Institute Stanic AK. Shashidharamurthy R. Bezbradica JS. Matsuki N. Yoshimura Y. Miyake S. Choi EY. Schell TD. Van Kaer L. Tevethia SS. Roopenian DC. Yamamura T. Joyce S. Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. 2003 Nov 1. J Immunol. 171(9):4539-51. National Institute of Allergy and Infectious Diseases National Heart, Lung, and Blood Institute Staveley-O'Carroll K. Schell TD. Jimenez M. Mylin LM. Tevethia MJ. Schoenberger SP. Tevethia SS. In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. 2003 Jul 15. J Immunol. 171(2):697-707. National Cancer Institute Schell TD. Mylin LM. Tevethia SS. Joyce S. The assembly of functional beta(2)-microglobulin-free MHC class I molecules that interact with peptides and CD8(+) T lymphocytes. 2002 Jul. Int Immunol. 14(7):775-82. National Cancer Institute National Heart, Lung, and Blood Institute Schell TD. Lippolis JD. Tevethia SS. Cytotoxic T lymphocytes from HLA-A2.1 transgenic mice define a potential human epitope from simian virus 40 large T antigen. 2001 Feb 1. Cancer Res. 61(3):873-9. National Cancer Institute Schell TD. Tevethia SS. Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen. 2001 Dec 15. J Immunol. 167(12):6947-56. National Cancer Institute Tevethia S. Beachy T. Schell T. Lippolis J. Newmaster R. Mylin L. Tevethia MJ. Role of CTL host responses and their implication for tumorigenicity testing and the use of tumour cells as vaccine substrate. 2001. Dev Biol (Basel). 106:109-21; discussion 143-60. National Cancer Institute Schell TD. Tevethia SS. Cytotoxic T lymphocytes in SV40 infections. 2001. Methods Mol Biol. 165:243-56. National Cancer Institute Schell TD. Knowles BB. Tevethia SS. Sequential loss of cytotoxic T lymphocyte responses to simian virus 40 large T antigen epitopes in T antigen transgenic mice developing osteosarcomas. 2000 Jun 1. Cancer Res. 60(11):3002-12. National Cancer Institute Mylin LM. Schell TD. Roberts D. Epler M. Boesteanu A. Collins EJ. Frelinger JA. Joyce S. Tevethia SS. Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. 2000 Aug. J Virol. 74(15):6922-34. National Institute of Allergy and Infectious Diseases National Cancer Institute National Heart, Lung, and Blood Institute Schell TD. Mylin LM. Georgoff I. Teresky AK. Levine AJ. Tevethia SS. Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice. 1999 Jul. J Virol. 73(7):5981-93. National Cancer Institute Brehm M. Samaniego LA. Bonneau RH. DeLuca NA. Tevethia SS. Immunogenicity of herpes simplex virus type 1 mutants containing deletions in one or more alpha-genes: ICP4, ICP27, ICP22, and ICP0. 1999 Apr 10. Virology. 256(2):258-69. National Cancer Institute National Institute of Allergy and Infectious Diseases Boesteanu A. Brehm M. Mylin LM. Christianson GJ. Tevethia SS. Roopenian DC. Joyce S. A molecular basis for how a single TCR interfaces multiple ligands. 1998 Nov 1. J Immunol. 161(9):4719-27. National Institute of Allergy and Infectious Diseases National Cancer Institute Newmaster RS. Mylin LM. Fu TM. Tevethia SS. Role of a subdominant H-2Kd-restricted SV40 tumor antigen cytotoxic T lymphocyte epitope in tumor rejection. 1998 May 10. Virology. 244(2):427-41. National Cancer Institute Fu TM. Mylin LM. Schell TD. Bacik I. Russ G. Yewdell JW. Bennink JR. Tevethia SS. An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. 1998 Feb. J Virol. 72(2):1469-81. National Cancer Institute Blaney JE. Nobusawa E. Brehm MA. Bonneau RH. Mylin LM. Fu TM. Kawaoka Y. Tevethia SS. Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity. 1998 Dec. J Virol. 72(12):9567-74. National Cancer Institute National Institute of Allergy and Infectious Diseases Tevethia SS. Mylin L. Newmaster R. Epler M. Lednicky JA. Butel JS. Tevethia MJ. Cytotoxic T lymphocyte recognition sequences as markers for distinguishing among tumour antigens encoded by SV40, BKV and JCV. 1998. Dev Biol Stand. 94:329-39. National Cancer Institute Brehm MA. Bonneau RH. Knipe DM. Tevethia SS. Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1. 1997 May. J Virol. 71(5):3534-44. National Cancer Institute National Institute of Allergy and Infectious Diseases Fu TM. Bonneau RH. Epler M. Tevethia MJ. Alam S. Verner K. Tevethia SS. Induction and persistence of a cytotoxic T lymphocyte (CTL) response against a herpes simplex virus-specific CTL epitope expressed in a cellular protein. 1996 Aug 1. Virology. 222(1):269-74. National Institute of Allergy and Infectious Diseases National Cancer Institute Mylin LM. Bonneau RH. Lippolis JD. Tevethia SS. Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. 1995 Nov. J Virol. 69(11):6665-77. National Cancer Institute Lippolis JD. Mylin LM. Simmons DT. Tevethia SS. Functional analysis of amino acid residues encompassing and surrounding two neighboring H-2Db-restricted cytotoxic T-lymphocyte epitopes in simian virus 40 tumor antigen. 1995 May. J Virol. 69(5):3134-46. National Cancer Institute Salvucci LA. Bonneau RH. Tevethia SS. Polymorphism within the herpes simplex virus (HSV) ribonucleotide reductase large subunit (ICP6) confers type specificity for recognition by HSV type 1-specific cytotoxic T lymphocytes. 1995 Feb. J Virol. 69(2):1122-31. National Institute of Allergy and Infectious Diseases National Institute of Mental Health Fu TM. Bonneau RH. Tevethia MJ. Tevethia SS. Simian virus 40 T antigen as a carrier for the expression of cytotoxic T-lymphocyte recognition epitopes. 1993 Nov. J Virol. 67(11):6866-71. National Cancer Institute Bonneau RH. Salvucci LA. Johnson DC. Tevethia SS. Epitope specificity of H-2Kb-restricted, HSV-1-, and HSV-2-cross-reactive cytotoxic T lymphocyte clones. 1993 Jul. Virology. 195(1):62-70. National Cancer Institute Bonneau RH. Fu TM. Tevethia SS. In vivo priming and activation of memory cytotoxic T-lymphocytes (CTL) by a chimeric simian virus 40 T antigen expressing an eight amino acid residue herpes simplex virus gB CTL epitope. 1993 Dec. Virology. 197(2):782-7. National Cancer Institute Tevethia SS. Epler M. Georgoff I. Teresky A. Marlow M. Levine AJ. Antibody response to human papovavirus JC (JCV) and simian virus 40 (SV40) T antigens in SV40 T antigen-transgenic mice. 1992 Sep. Virology. 190(1):459-64. National Cancer Institute Deckhut AM. Tevethia SS. Effect of point mutations in the native simian virus 40 tumor antigen, and in synthetic peptides corresponding to the H-2Db-restricted epitopes, on antigen presentation and recognition by cytotoxic T lymphocyte clones. 1992 May 15. J Immunol. 148(10):3012-20. National Cancer Institute Deckhut AM. Lippolis JD. Tevethia SS. Comparative analysis of core amino acid residues of H-2D(b)-restricted cytotoxic T-lymphocyte recognition epitopes in simian virus 40 T antigen. 1992 Jan. J Virol. 66(1):440-7. National Cancer Institute Lill NL. Tevethia MJ. Hendrickson WG. Tevethia SS. Cytotoxic T lymphocytes (CTL) against a transforming gene product select for transformed cells with point mutations within sequences encoding CTL recognition epitopes. 1992 Aug 1. J Exp Med. 176(2):449-57. National Cancer Institute Deckhut AM. Tevethia MJ. Haggerty S. Frisque RJ. Tevethia SS. Localization of common cytotoxic T lymphocyte recognition epitopes on simian papovavirus SV40 and human papovavirus JC virus T antigens. 1991 Jul. Virology. 183(1):122-32. National Cancer Institute Tevethia SS. Lewis M. Tanaka Y. Milici J. Knowles B. Maloy WL. Anderson R. Dissection of H-2Db-restricted cytotoxic T-lymphocyte epitopes on simian virus 40 T antigen by the use of synthetic peptides and H-2Dbm mutants. 1990 Mar. J Virol. 64(3):1192-200. National Cancer Institute Tevethia SS. Recognition of simian virus 40 T antigen by cytotoxic T lymphocytes. 1990 Feb. Mol Biol Med. 7(1):83-96. National Cancer Institute Tanaka Y. Tevethia SS. Loss of immunorecessive cytotoxic T lymphocyte determinant V on SV40 T antigen following cocultivation with site-specific cytotoxic T lymphocyte clone Y-5. 1990. Intervirology. 31(2-4):197-202. National Cancer Institute Tanaka Y. Anderson RW. Maloy WL. Tevethia SS. Localization of an immunorecessive epitope on SV40 T antigen by H-2Db-restricted cytotoxic T-lymphocyte clones and a synthetic peptide. 1989 Jul. Virology. 171(1):205-13. National Cancer Institute Jennings SR. Fresa KL. Lippe PA. Milici JE. Tevethia SS. Frequency analysis of simian virus 40-specific cytotoxic T lymphocyte precursors in the high responder C57BL/6 mouse strain. 1988 Oct. J Gen Virol. 69 ( Pt 10):2493-503. National Institute of Allergy and Infectious Diseases National Cancer Institute Tanaka Y. Tevethia SS. In vitro selection of SV40 T antigen epitope loss variants by site-specific cytotoxic T lymphocyte clones. 1988 Jun 15. J Immunol. 140(12):4348-54. National Cancer Institute Bates MP. Jennings SR. Tanaka Y. Tevethia MJ. Tevethia SS. Recognition of simian virus 40 T antigen synthesized during viral lytic cycle in monkey kidney cells expressing mouse H-2Kb- and H-2Db-transfected genes by SV40-specific cytotoxic T lymphocytes leads to the abrogation of virus lytic cycle. 1988 Jan. Virology. 162(1):197-205. National Institute of Allergy and Infectious Diseases National Cancer Institute Anderson RW. Tevethia MJ. Kalderon D. Smith AE. Tevethia SS. Fine mapping two distinct antigenic sites on simian virus 40 (SV40) T antigen reactive with SV40-specific cytotoxic T-cell clones by using SV40 deletion mutants. 1988 Jan. J Virol. 62(1):285-96. National Cancer Institute Tanaka Y. Tevethia MJ. Kalderon D. Smith AE. Tevethia SS. Clustering of antigenic sites recognized by cytotoxic T lymphocyte clones in the amino terminal half of SV40 T antigen. 1988 Feb. Virology. 162(2):427-36. National Cancer Institute Tanaka Y. Tevethia SS. Differential effect of adenovirus 2 E3/19K glycoprotein on the expression of H-2Kb and H-2Db class I antigens and H-2Kb- and H-2Db-restricted SV40-specific CTL-mediated lysis. 1988 Aug. Virology. 165(2):357-66. National Cancer Institute